Grant: Project Grant

Triple-negative breast cancer (TNBC) represents the tumor type with the poorest outcome. TNBCs frequently harbor alterations in the MYC oncogene, for which no direct treatment currently exists. To identify potential vulnerabilities in TNBC, we designed a cellular model expressing the MYC oncogene. We found that MYC promotes the expression of many receptors at the surface of cancer cells that could be targeted to treat TNBC. In this project, we will use breast cancer cells in culture, as well as pre-clinical models of TNBC, to assess the therapeutic targeting of these novel cell-surface receptors. Through this work, we hope to characterize these receptors in TNBC, while also providing answers about their druggability for potential TNBC treatment.